NCT05391048View on ClinicalTrials.gov

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

July 21, 2022

Study Completion Date

July 21, 2022

Conditions
Solid Tumor
Interventions
DRUG

IMP4297(20mg)

Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)

DRUG

IMP4297(10mg)

Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)

Trial Locations (1)

221000

Xuzhou Central Hospital, Xuzhou

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT05391048 - An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition | Biotech Hunter | Biotech Hunter